← Eichor
Study identifier: NCT05329714 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PVRI GoDeep Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension

Condition: Pulmonary Hypertension · Global Health  ·  Sponsor: University of Giessen

PhaseN/A
Planned participants40000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersYes

About this study

PVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. It will be operated under the auspices of the University of Giessen/Giessen PH center. Combining deep phenotyping with worldwide outreach, PVRI-GoDeep aims to offer insights into specific geographical and ethnical profiles of PH, to deepen the epidemiological, clinical and molecular understanding of this disease and to promote strategies for improved individualized treatment of PH patients.

This description comes directly from the study's public registry record.

Talk to the study team

Raphael W Majeed  ·  +49 641 985 42502  ·  raphael.majeed@innere.med.uni-giessen.de

Always discuss trial participation with your own doctor first.

Locations (1)

University Giessen PH CenterGiessen, Hesse, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05329714